| Q64378710 | Q64378710 |
| Q40528468 | A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer |
| Q36419822 | Adenoviral vectors--how to use them in cancer gene therapy? |
| Q39065475 | Adenovirus serotype 11 causes less long-term intraperitoneal inflammation than serotype 5: implications for ovarian cancer therapy |
| Q36496709 | Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma |
| Q43573413 | Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl |
| Q33713224 | Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice |
| Q92058791 | Artificially cloaked viral nanovaccine for cancer immunotherapy |
| Q36226789 | Cancer-specific gene therapy. |
| Q34302149 | Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. |
| Q36695785 | Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo |
| Q30421664 | Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics |
| Q48859616 | Diffuse encephaloventriculitis and substantial leukoencephalopathy after intraventricular administration of recombinant adenovirus |
| Q36868494 | Engineering targeted viral vectors for gene therapy |
| Q40223019 | Enriching suicide gene bearing tumor cells for an increased bystander effect |
| Q34305438 | Epigenetic therapies as a promising strategy for overcoming chemoresistance in epithelial ovarian cancer |
| Q35924210 | Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. |
| Q75353680 | Focus on epithelial ovarian cancer |
| Q90185529 | Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter |
| Q33658229 | Frequent downregulation of miR-34 family in human ovarian cancers |
| Q33516121 | Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China |
| Q36265644 | Gene therapy imaging in patients for oncological applications. |
| Q24680275 | Gene therapy in clinical medicine |
| Q36922247 | Gene therapy of gynaecological diseases |
| Q40309654 | Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors |
| Q35648549 | Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. |
| Q36429492 | Gene therapy vector design strategies for the treatment of cancer |
| Q36464907 | Gene transfer approaches for gynecological diseases |
| Q35596405 | Gene transfer: Bax to the future for cancer therapy |
| Q39851900 | Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. |
| Q40257577 | Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. |
| Q40002462 | In vivo restoration of RhoB expression leads to ovarian tumor regression. |
| Q33205530 | Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma |
| Q64238152 | Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy |
| Q36387940 | Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer |
| Q44530268 | Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma |
| Q50130134 | Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer |
| Q35694610 | MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. |
| Q64054715 | Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53 |
| Q40318210 | Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53. |
| Q37888659 | Molecular targeted therapy in ovarian cancer: what is on the horizon? |
| Q64079678 | Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer |
| Q37448942 | Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time |
| Q36318189 | Oncolytic adenoviruses - selective retargeting to tumor cells |
| Q38450392 | Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans |
| Q37718560 | OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution |
| Q84605146 | Ovarian cancer |
| Q34086819 | Ovarian cancer development and metastasis |
| Q40361993 | Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy |
| Q36776863 | Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex |
| Q33748323 | Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead |
| Q35864258 | Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. |
| Q37191174 | Pharmacological activation of p53 in cancer cells |
| Q93001945 | Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma |
| Q35073239 | Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model |
| Q89389518 | Recent Progress in Gene Therapy for Ovarian Cancer |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q34627083 | Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation |
| Q36713156 | Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer |
| Q37942529 | Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors |
| Q38187890 | Revisiting p53 for cancer-specific chemo- and radiotherapy: ten years after |
| Q33940195 | Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC) |
| Q34687279 | Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells |
| Q40062926 | Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis |
| Q34909902 | Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer |
| Q36158708 | Targeted therapy for epithelial ovarian cancer |
| Q35795073 | Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils |
| Q61945431 | Terapia génica: realidades actuales y expectativas |
| Q38635932 | The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer |
| Q36180358 | The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines |
| Q37325095 | The mitochondrial p53 pathway |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q35904008 | The use of gene therapy in cancer research and treatment |
| Q37803120 | Translating p53 into the clinic. |
| Q30465097 | Translational imaging endpoints to predict treatment response to novel targeted anticancer agents |
| Q40297448 | Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells |
| Q33820871 | Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition |
| Q40036993 | Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. |
| Q37316548 | Why does cytotoxic chemotherapy cure only some cancers? |
| Q35180856 | Wild-type p53 controls cell motility and invasion by dual regulation of MET expression |
| Q36558001 | p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction |